JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2018. Vol. 63. No. 6. P. 59 –64
RADIATION THERAPY
DOI: 10.12737/article_5c0b90d10ff212.78053112
V.A. Solodkiy, V.M. Sotnikov, S.D. Trotsenko, V.P. Kharchenko, V.D. Chkhikvadze, N.V. Nudnov, G.A. Panshin, A.A. Morgunov
Non-Small Cell Lung Cancer Recurrences After Surgical and Combined Modality Treatment with Postoperative Radiation Therapy
Russian Scientific Center of Roentgenoradiology, Moscow, Russia. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
V.A. Solodkiy – Dr. Sci. Med., Prof., Academician of RAS, Director; V.M. Sotnikov – Dr. Sci. Med., Prof., Head of Lab.;
S.D. Trotsenko – PhD Med., Radiologist; V.P. Kharchenko – Dr. Sci. Med., Prof., Academician of RAS, Scientific Supervisor;
V.D. Chkhikvadze – Dr. Sci. Med., Prof., Head of Dep.; N.V. Nudnov – Dr. Sci. Med., Prof., Deputy Director;
G.A. Panshin – Dr. Sci. Med., Prof., Head of Dep.; A.A. Morgunov – Senior Researcher
Abstract
Purpose: To compare the patterns of the relapses after the surgical and combined modality treatment of non-small cell lung cancer (NSCLC) with the postoperative radiotherapy (PORT).
Material and methods: The comparative evaluation of the patterns of the relapses was carried out in 528 NSCLC patients with the IA–IIIB stage after surgical treatment (n = 174) and combined modality treatment (n = 354) using PORT in the hypofractionation regimen 3 Gy/fraction, 5 times a week, TD 36–39 Gy (EQD2 = 43.2–46.8 Gy, α/β = 3) and classical fractionation 2 Gy/fraction, 5 times a week, TD 44 Gy.
Results: The local and the regional relapses developed from 2 to 59 months after treatment, most often in the first three years of follow-up (median 15 months). The local and the regional relapses were statistically significantly more frequent in the surgical treatment group (31.6 % vs 7.1 %). The frequency of the distant metastases in the both groups was not statistically different (46.6 % vs 42.3 %), however, in the surgical treatment group, the distant metastases were more often combined with the locoregional relapses (18.4 % vs 4.5 %). Surgery+PORT in comparison with surgical treatment alone reduces the incidence of locoregional recurrence at the central location of the tumor (8.8 % vs 40.0 %), peripheral non-small cell lung cancer (5.2 % vs 26.0 %), with squamous histological type of tumor (8.4 % vs 37.5 %) and in adenocarcinoma (4.6 % vs 26.4 %), regardless of the volume of surgical treatment (pneumonectomy – 7.0 % vs 47, 1 %, p = 0.0002, lobectomy and bilobectomy – 7.1 % vs 20.6 %, p = 0.001, segmentectomy – 7.1 % vs 50.0 %, p = 0.0001). In the subgroup of patients undergoing adjuvant chemotherapy and PORT, the local, regional and locoregional relapses were statistically significantly less common than in the group of non-small cell lung cancer patients who received only adjuvant chemotherapy (3.9 % vs 17.5 %, p = 0.002, 5.4 % vs 23.8 %, p = 0.001, 6.2 % vs 36.5 %, p = 0.0001). The number of combined relapses (local and/or regional relapses + distant metastases) was actually four times less in all subgroups of patients with PORT (4.7 % vs 20.6 %, p = 0.001).
Conclusion: PORT as the part of combined treatment of non-small cell lung cancer statistically significantly reduces the incidence of the local, regional, locoregional and combined relapses in the squamous cell lung cancer and adenocarcinoma, central and peripheral localization of the tumor, after surgical treatment in the volume of pneumonectomy, lob-bilobectomy and segmentectomy, and when using with or without adjuvant chemotherapy.
Key words: lung cancer, surgical treatment, combined modality treatment, postoperative radiation therapy, the characteristic of recurrences
REFERENCE
- UICC International Union Against Cancer: Sobin LH, Gospodarowicz MK, Wittekind Ch. // In: TNM classification of malignant tumours. 7th edition. Chichester: Wiley-Blackwell. 2009:138-46.
- Billiet C, Peeters S, Decaluwé H, et al. Postoperative radiotherapy for lung cancer: Is it worth the controversy? Cancer Treat Rev. 2016;51:417-25.
- Vansteenkiste J, De Ruysscher D, Eberhardt WE, et al. ESMO Guidelines Working Group. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(6):89-98.
- De Ruysscher D, Belderbos J, Reymen B, et al. State of the art radiation therapy for lung cancer 2012: a glimpse of the future. Clin Lung Cancer. 2013;14(2):89-95.
- Solodky VA, Sotnikov VM, Trotsenko SD, et al. Characteristics of recurrences after surgical and combined treatment of non-small cell lung cancer. Problems in Onсology. 2017;63(4):639-44. (Russian).
- Matthews MJ, Kanhouwa S, Pickren J, Robinette D. Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer. Cancer Chemother Rep. 1973;(4)2:63-7.
- Kharchenko VP, Chkhikvadze VD, Gvarishvili AA, Vasilyev OA. Surgical and combined treatment of non-small cell lung cancer. Vestnik RUDN. Seria Medicina. 2005;29(1):13-16. (Russian).
- Varlotto JM, Yao AN, DeCamp MM, et al. Nodal stage of surgically resected non-small cell lung cancer and its effect on recurrence patterns and overall survival. Int J Radiat Oncol Biol Phys. 2015;91(4):765-73.
- Robinson CG, Patel AP, Bradley JD, et al. Postoperative Radiotherapy for Pathologic N2 Non–Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: A Review of the National Cancer Data Base. J Clin Oncol. 2015;33(8):870-6.
- Su S, Scott WJ, Allen MS, et al. Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial. J Thorac Cardiovasc Surg. 2014;147(2):747-52.
- Kharchenko VP, Chkhikvadze VD. Surgical and combined treatment of non-small cell lung cancer. Problems in Onсology. 2009;55(4):455-8. (Russian).
- Shen W, Ji J, Zuo Y, et al. Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with IIIA-pN2 non-small cell lung cancer: An early closed randomized controlled trial. Radiotherapy and Oncology. 2014;110(1):120-5.
- Warren M, Webster G, Ryder D, et al. An isotoxic planning comparison study for stage II–III non-small cell lung cancer: is intensity-modulated radiotherapy the answer? Clinical Oncology. 2014;26(8):461-7.
For citation: Solodkiy VA, Sotnikov VM, Trotsenko SD, Kharchenko VP, Chkhikvadze VD, Nudnov NV, Panshin GA, Morgunov AA. Non-Small Cell Lung Cancer Recurrences After Surgical and Combined Modality Treatment with Postoperative Radiation Therapy. Medical Radiology and Radiation Safety. 2018;63(6):59-64. (Russian).
PDF (RUS) Full-text article (in Russian)